Horizon Therapeutics Plc (HZNP)

26.34
NASDAQ : Health Technology
Prev Close 26.43
Day Low/High 26.05 / 26.66
52 Wk Low/High 16.56 / 29.44
Avg Volume 1.84M
Exchange NASDAQ
Shares Outstanding 186.45M
Market Cap 4.93B
EPS -0.50
P/E Ratio 68.05
Div & Yield N.A. (N.A)
New Lifetime High Reached: Horizon Pharma (HZNP)

New Lifetime High Reached: Horizon Pharma (HZNP)

Trade-Ideas LLC identified Horizon Pharma (HZNP) as a new lifetime high candidate

Horizon Pharmaceuticals (HZNP) Stock is Today's 'Chart of the Day'

Horizon Pharmaceuticals (HZNP) Stock is Today's 'Chart of the Day'

Horizon Pharmaceuticals (HZNP) stock performance is the subject of today's Trifecta Stocks 'Chart of the Day' analysis.

Horizon Pharma Is Ready for a Boost

Horizon Pharma Is Ready for a Boost

Horizon Pharma's volume trends have been very positive.

Chart of the Day: HZNP

Horizon Pharma's volume trends have been very positive.

Today's Dead Cat Bounce Stock: Horizon Pharma (HZNP)

Today's Dead Cat Bounce Stock: Horizon Pharma (HZNP)

Trade-Ideas LLC identified Horizon Pharma (HZNP) as a "dead cat bounce" (down big yesterday but up big today) candidate

Horizon Pharma (HZNP) Stock Tanks on Mixed Earnings

Horizon Pharma (HZNP) Stock Tanks on Mixed Earnings

Horizon Pharma (HZNP) reported first quarter earnings that missed expectations though revenue topped estimates.

'Mad Money' Lightning Round: Sell, Sell, Sell Transocean

'Mad Money' Lightning Round: Sell, Sell, Sell Transocean

Cramer says Horizon Pharmaceuticals is a winner but he's no fan of Oneok.

Jim Cramer's 'Mad Money' Recap: The 5 Ingredients in Today's Rally Recipe

Jim Cramer's 'Mad Money' Recap: The 5 Ingredients in Today's Rally Recipe

A rejuvenated stock market is still possible, Cramer says.

New Lifetime High For Horizon Pharma (HZNP)

New Lifetime High For Horizon Pharma (HZNP)

Trade-Ideas LLC identified Horizon Pharma (HZNP) as a new lifetime high candidate

Horizon Pharma (HZNP) Stock Rises in After-Hours Trading Following Pricing of Secondary Offering

Horizon Pharma (HZNP) Stock Rises in After-Hours Trading Following Pricing of Secondary Offering

Horizon Pharma (HZNP) shares are climbing in after-hours trading today after the company priced its secondary public offering at $28.25 per share.

Horizon Pharma (HZNP) Trading With Heavy Volume Before Market Open

Horizon Pharma (HZNP) Trading With Heavy Volume Before Market Open

Trade-Ideas LLC identified Horizon Pharma (HZNP) as a pre-market mover with heavy volume candidate

Jim Cramer's 'Mad Money' Recap: 6 Positive Things You Should Keep in Focus

Jim Cramer's 'Mad Money' Recap: 6 Positive Things You Should Keep in Focus

From earnings to activist investors, Cramer said investors need to focus on the good things now happening in the markets.

Horizon Pharma (HZNP) Stock Falls in After-Hours Today Following Public Share Offering Announcement

Horizon Pharma (HZNP) Stock Falls in After-Hours Today Following Public Share Offering Announcement

Horizon Pharma (HZNP) shares are falling after-hours after announcing a 12 million public share offering.

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

The recent bid by Mylan to acquire Perrigo offers the latest example of pharma companies that have been seeking growth opportunities.

Jim Cramer's 'Mad Money' Recap: Ignore the Chatter, Stick With Best-of-Breed Stocks

Jim Cramer's 'Mad Money' Recap: Ignore the Chatter, Stick With Best-of-Breed Stocks

Many investors are getting caught up in the takeover speculation game, Cramer warns. Don't do it.

Trade-Ideas: Horizon Pharma (HZNP) Is Today's Post-Market Leader Stock

Trade-Ideas: Horizon Pharma (HZNP) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Horizon Pharma (HZNP) as a post-market leader candidate

Say It With Me: Specialty Pharma

These companies are the hottest thing going.

Mylan Deal the Rx for Drug Stocks

Even the second-tier biotechs are taking off.

Feeling Good About Pharmaceuticals

With so much M&A action, now's the time to invest in the sector.

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks

Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.

Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference

Jim Cramer's 'Mad Money' Recap: Good Headlines Make All the Difference

It's nice to see the flow of money has reversed from last week's relentless selloff, Cramer says.

Market Wrap: Out Like a Lion

Stocks post solid gains with the S&P breaking a losing streak.

Market News: Auspex Pharmaceuticals, Catamaran, Horizon Pharma

Market News: Auspex Pharmaceuticals, Catamaran, Horizon Pharma

The stock markets in the United States rallied today driven by optimism among investors that central banks will support the global economic growth. The markets also benefitted from reports on corporat...

Unilife Surges as Biotech Stocks Catch Bid

Biotech sector gets a boost from three sizable acquisition announcements.

Stock Markets Soar on Trifecta of Good News

Stock Markets Soar on Trifecta of Good News

Stocks recapture positive territory for the year on a spate of pharma deals, as well as positive news from the Fed and China.

Energy Sector Leads Stock Markets Higher as Rally Rolls On

Energy Sector Leads Stock Markets Higher as Rally Rolls On

Stocks recapture positive territory for the year.

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion

Teva Buys Tourette Syndrome Drug Firm Auspex for $3.2 Billion

The Israeli drug company thinks the biopharmaceutical drug developer will strengthen its position in its core central nervous system segment.

Street Check: Hyperion Bought After Brean Noted Takeout Potential Last Month

Street Check: Hyperion Bought After Brean Noted Takeout Potential Last Month

Shares of Hyperion Therapeutics rose 8% this morning after the company announced that it had agreed to be acquired for $46 per share by Horizon Pharma.

Teva Pharmaceutical Swallows Auspex to Strengthen Its Drug Pipeline

Teva Pharmaceutical Swallows Auspex to Strengthen Its Drug Pipeline

Israeli drug company Teva Pharmaceutical Industries is buying Auspex Pharmaceuticals, with its portfolio of drugs to treat Tourette Syndrome, Huntington's chorea and a variety of other maladies.

Stocks Reclaim Year-to-Date Gains as China Talks Monetary Easing

Stocks Reclaim Year-to-Date Gains as China Talks Monetary Easing

Stocks begin the holiday-shortened week with a bounce following a deluge of big pharma M&A deals on Monday morning.

TheStreet Quant Rating: C+ (Hold)